BOSTON, Jan. 03, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, California on Monday, January 8, 2024 at 4:30 p.m. EST / 1:30 p.m. PST. HIL-214, HilleVax's investigational virus-like particle (VLP) based vaccine for the prevention of moderate-to-severe norovirus-related acute gastroenteritis, and the related ongoing Phase 2b study NEST-IN1 will be topics of discussion.
Presentation details: | |
Date: | Monday, January 8, 2024 |
Time: | 1:30 – 2:10 p.m. Pacific Standard Time (PST) |
Moderator: | Eric Joseph, Ph.D. |
Location: | Elizabethan C Room, Westin St. Francis Hotel, San Francisco |
HilleVax Participant: | Robert Hershberg, MD, PhD, Chairman and Chief Executive Officer |
Webcast & Audit Visual: | https://jpmorgan.metameetings.net/events/healthcare24/sessions/49552-hillevax/webcast?gpu_only=true&kiosk=true |
About HilleVax
HilleVax is a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines. Its initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection. Globally, norovirus is estimated to result in over approximately 700 million cases of ...